Evidence map›Paper›PMID 36531671›Full record

ArticleResearch and practice in thrombosis and haemostasis2023

Effects of convalescent plasma infusion on the ADAMTS13-von Willebrand factor axis and endothelial integrity in patients with severe and critical COVID-19.

Quan Zhang, Zhan Ye, Paul McGowan, Christopher Jurief, Andrew Ly, Antonia Bignotti, Noritaka Yada, X Long Zheng

Open access · goldAbstract read
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Endotheliopathy in Acute COVID-19 and Long COVID.International journal of molecular sciences · 2023
    Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Quan ZhangDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Zhan YeDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Paul McGowanDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Christopher JuriefDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Andrew LyDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Antonia BignottiDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Noritaka YadaDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
X Long ZhengDepartment of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
University of Kansas Medical Center · US

Funding

Pathogenesis of thrombotic microangiopathiesR01HL164016 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI X. Long Zheng · 2023 to 2026
$2.1M
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic PurpuraR01HL144552 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHENG, X. LONG · 2019 to 2022
$1.8M
Mechanism underlying cofactor-dependent proteolysis of von Willebrand FactorR01HL157975 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHANG, XIAOHUI FRANK, ZHENG, X. LONG · 2022 to 2025
$1.8M
NHLBI NIH HHS R01 HL144552NHLBI NIH HHS R01 HL157975NHLBI NIH HHS R01 HL164016
6 · The paper itself

Abstract

Background: Convalescent plasma infusion (CPI) was given to patients with COVID-19 during the early pandemic with mixed therapeutic efficacy. However, the impacts of CPI on the ADAMTS13-von Willebrand factor (VWF) axis and vascular endothelial functions are not known. Objectives: To determine the impacts of CPI on the ADAMTS13-VWF axis and vascular endothelial functions. Methods: Sixty hospitalized patients with COVID-19 were enrolled in the study; 46 received CPI and 14 received no CPI. Plasma ADAMTS13 activity, VWF antigen, endothelial syndecan-1, and soluble thrombomodulin (sTM) were assessed before and 24 hours after treatment. Results: Patients with severe and critical COVID-19 exhibited significantly lower plasma ADAMTS13 activity than the healthy controls. Conversely, these patients showed a significantly increased VWF antigen. This resulted in markedly reduced ratios of ADAMTS13 to VWF in these patients. The levels of plasma ADAMTS13 activity in each patient remained relatively constant throughout hospitalization. Twenty-four hours following CPI, plasma ADAMTS13 activity increased by ∼12% from the baseline in all patients and ∼21% in those who survived. In contrast, plasma levels of VWF antigen varied significantly over time. Patients who died exhibited a significant reduction of plasma VWF antigen from the baseline 24 hours following CPI, whereas those who survived did not. Furthermore, patients with severe and critical COVID-19 showed significantly elevated plasma levels of syndecan-1 and sTM, similar to those found in patients with immune thrombotic thrombocytopenic purpura. Both syndecan-1 and sTM levels were significantly reduced 24 hours following CPI. Conclusion: Our results demonstrate the relative deficiency of plasma ADAMTS13 activity and endothelial damage in patients with severe and critical COVID-19, which could be modestly improved following CPI therapy.

Indexed as

ADAMTS13ADAMTS13, A Disintegrin And Metalloprotease with ThromboSpondin Type 1 Repeats, 13convalescent plasmaCOVID-19COVID-19, Coronavirus disease 2019CPI, Convalescent plasma infusionendothelial injuryIQR, Interquartile rangeiTTP, Immune thrombotic thrombocytopenic purpurasTM, Soluble thrombomodulinsydecan-1thrombomodulinTPE, Therapeutic plasma exchangeVWFVWF, von Willebrand factor

Identifiers

PMID36531671
PMCPMC9744678
OpenAlexW4311930030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.